CBMR researchers discover that a power failure in your fat cells could short-circuit your health

DIABETES The energy metabolism of the body’s so-called brown fat cells is controlled by the fat molecule cardiolipin, researchers from the University of Copenhagen have discovered in a new study. The research reveals that absence of cardiolipin in fat cells is causally linked to pre-diabetes and type 2 diabetes.

A specialized fat molecule, called cardiolipin, that is made within the body’s own fat cells, is far more significant to the body’s overall state of health than previously realized.

Large amounts of cardiolipin produced in the fat cells’ mitochondria – or so-called powerhouses – result in stronger calorie-burning while low amounts of the molecule are related to obesity and type 2 diabetes, a new study conducted at Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, shows.

- Brown fat is a fascinating and unique type of fat tissue that actually burns calories rather than stores them. Now we have learned that the fat molecule, cardiolipin, functions almost like an “on-off switch” for the activity of our brown fat. Switching off production of cardiolipin in mice leads to insulin resistance, which is the cornerstone of diabetes, says Associate Professor Zach Gerhart-Hines, senior author of the study.

Burn More CaloriesA brown fat cell functions as a microscopic biological furnace that warms the body. The study, which has just been published in the scientific journal, Cell Metabolism, started out by examining what happens in the fat cells of mice that are exposed to cold temperature, where brown fat is pushed to burn energy at full throttle. The researchers found that the mitochondria produced a lot of the molecule, cardiolipin. However, in order to understand how this could affect energy balance and health, they had to develop new tools.

- We generated mouse models in which we could switch off cardiolipin production in brown fat. After decreasing cardiolipin levels, the mice became insulin resistant and thus provided a clear link to diabetes. What really surprised us was that when we turned up the production of cardiolipin in both mouse and human fat cells, we increased the amount of calories the fat cells were able to burn, Zach Gerhart-Hines explains.

Conclusions Supported by Human Genetics and Diabetic PatientsThe researchers further uncovered promising evidence that strongly suggests the scientific findings are relevant to humans.

When the researchers investigated the genetics of metabolic disease, they found that people with a gene mutation linked to low cardiolipin production have a higher risk of being overweight and developing type 2 diabetes than others.

The researchers also examined the levels of the enzyme that makes cardiolipin in fat cells from healthy and diabetic patients. They found that fat cells from healthy, insulin-sensitive people had significantly more cardiolipin-producing enzyme.

- We’re excited that what we find in the petri dish and animal models seems to also be true in humans. This could open up new approaches to improve metabolic health by finding ways to boost the amount of cardiolipin in the body’s fat cells, says Elahu Sustarsic, the postdoctoral researcher at CBMR who led the studies.

Boosting Brown Fat Power in the FutureThis work has revealed for the first time that a single fat molecule in the powerhouse of fat cells can have a profound influence on the health of the whole body. The researchers now hope to uncover ways to boost cardiolipin in fat cells to increase insulin sensitivity and combat metabolic disease.

The highly collaborative effort is the result of several research groups’ cross-disciplinary exploration of the brown fat cells’ production of cardiolipin. Researchers from Harvard Medical School in the US, the Helmholtz Diabetes Center in Germany, and several Danish institutions including the University of Southern Denmark and University of Copenhagen have contributed to the project.

The study was funded by the European Research Council, the Independent Research Fund Denmark – Medical Sciences, the American National Institute of Diabetes and Digestive and Kidney Diseases, the Danish Diabetes Academy, and the Novo Nordisk Foundation.